Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.

Joleen M HubbardJun YinErin L SchenkRui QinJoel M ReidCarrie StrandJack FiskumMichael MenefeeGrace LinL Austin DoylePercy IvyCharles ErlichmanAlex AdjeiPaul HaluskaBrian A Costello

Published in: Investigational new drugs (2021)

Cediranib and selumetinib in combination on a continuous schedule was not tolerable, with patients experiencing cardiovascular and other DLTs. Intermittent schedules may be needed to establish a safe and tolerable combination of cediranib and selumetinib.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
high intensity